MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Catalyst Biosciences ROA Ratio 2011-2026 | CBIO
Annual ROA Ratio Catalyst Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.35 | 5.09 | -157.98 | -59.3 | -55.99 | -24.06 | -54.57 | -44.49 | -21.23 | -29.13 | -32.02 | -3.69 | -3.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.09 | -157.98 | -42.62 |
Quarterly ROA Ratio Catalyst Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.91 | 8.47 | 11.19 | 14.18 | 89.55 | 162.64 | 189.3 | 128.28 | 112.53 | 21.42 | 52.93 | 10.09 | -22.04 | -38.43 | -119.94 | -70.56 | -87.46 | -72.23 | -70.84 | -39.36 | -52.26 | -48.24 | -44.04 | -42.18 | -48.34 | -41.6 | -32.81 | -15.38 | -30.05 | -38.55 | -48.23 | -40.01 | -52.53 | -50.4 | -48.21 | -34.64 | -42.02 | -36.76 | -26.55 | -21.23 | -57.53 | -100.65 | -100.03 | -97.46 | -307.21 | -265.67 | -272.3 | -276.28 | -31.23 | -26.54 | -10.41 | -3.69 | 0.88 | 1.53 | -6.99 | -3.3 | -3.51 | -0.87 | 4.88 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 189.3 | -307.21 | -34.93 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Adagene
ADAG
|
-37.44 | $ 2.34 | -6.02 % | $ 132 M |  China |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.97 | 1.34 % | $ 5.29 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Biogen
BIIB
|
5.82 | $ 173.65 | 1.2 % | $ 25.3 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
BioNTech SE
BNTX
|
65.02 | $ 117.58 | 1.38 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
-32.74 | $ 4.16 | -6.0 % | $ 116 M | France |
 |
BioXcel Therapeutics
BTAI
|
-155.46 | $ 1.79 | -1.64 % | $ 4.54 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 3.15 | 1.61 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 233.81 | -0.67 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
5.51 | $ 9.74 | -0.05 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-42.06 | $ 64.11 | 1.11 % | $ 7.18 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.12 | $ 67.54 | 0.74 % | $ 9.03 B | USA |
 |
Compugen Ltd.
CGEN
|
-12.38 | $ 2.06 | -1.67 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.43 | -0.78 % | $ 9.64 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
10.11 | $ 26.33 | 1.58 % | $ 1.28 B | USA |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 2.23 | 8.01 % | $ 210 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-2.11 | $ 13.56 | 1.27 % | $ 4.19 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Celldex Therapeutics
CLDX
|
-19.92 | $ 26.55 | 2.43 % | $ 1.71 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
0.11 | $ 94.47 | 1.64 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |